Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

811
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
811
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

724
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
724
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

812
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
812
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

594
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
594
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

649
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
649
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

887
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
887

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incremental prognostic value of intensity-weighted regional calcification scoring using contrast CT imaging in TAVR.

European heart journal. Imaging methods and practice·2024
Same author

COVID-19-Related Thrombotic and Bleeding Events in Adults With Congenital Heart Disease.

JACC. Advances·2024
Same author

COVID-19 mRNA Vaccination-Induced Myopericarditis in an Otherwise Healthy Young Male: An Evidence-Based Approach to Differentiating From Perimyocarditis.

Cureus·2024
Same author

The Impact of the COVID-19 Pandemic Restrictions on the Provision of Adult Congenital Heart Disease Care Across Canada: A National Survey.

CJC pediatric and congenital heart disease·2023
Same author

Adult Congenital Heart Disease Care in Canada: Has Quality of Care Improved in the Last Decade?

The Canadian journal of cardiology·2023
Same author

Reducing Morbidity and Mortality in Patients With Coarctation Requires Systematic Differentiation of Impacts of Mixed Valvular Disease on Coarctation Hemodynamics.

Journal of the American Heart Association·2022

Related Experiment Video

Updated: Apr 19, 2026

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs
08:19

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs

Published on: July 12, 2022

3.8K

Left ventricular non-compaction: from recognition to treatment.

Javier Ganame1

  • 1Department of Medicine, Division of Cardiology, McMaster University, 50 Charlton Ave East, Hamilton, Ontario, Canada, L8N 4A6. javierganame@gmail.com.

Current Pharmaceutical Design
|December 9, 2014
PubMed
Summary

Left ventricular non-compaction (LVNC) is a myocardial phenotype with genetic heterogeneity, often a morphological expression of other diseases. Diagnosis involves imaging and genetic assessment for tailored heart failure therapy.

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.3K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Related Experiment Videos

Last Updated: Apr 19, 2026

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs
08:19

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs

Published on: July 12, 2022

3.8K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.3K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Area of Science:

  • Cardiology
  • Genetics
  • Medical Imaging

Background:

  • Left ventricular non-compaction (LVNC) is characterized by a distinct thickened, two-layered myocardium.
  • Recent advances provide significant insight into LVNC's etiology, embryogenesis, genetics, diagnosis, and outcomes.
  • LVNC is increasingly recognized as a myocardial phenotype with genetic heterogeneity, not necessarily a distinct cardiomyopathy.

Purpose of the Study:

  • To review the current understanding of left ventricular non-compaction (LVNC).
  • To highlight LVNC's morphological features, genetic basis, clinical presentations, and diagnostic approaches.
  • To discuss therapeutic strategies for LVNC.

Main Methods:

  • Review of current literature on left ventricular non-compaction (LVNC).
  • Analysis of diagnostic modalities including non-invasive imaging and genetic assessment.
  • Evaluation of clinical features, outcomes, and therapeutic interventions.

Main Results:

  • LVNC exhibits a unique morphology detectable by non-invasive imaging.
  • It presents as a phenotype with genetic heterogeneity, often linked to other cardiomyopathies or genetic syndromes.
  • Clinical manifestations range from asymptomatic cases to severe heart failure, arrhythmias, and sudden cardiac death.

Conclusions:

  • LVNC is a morphological expression of various underlying conditions, emphasizing the need for comprehensive diagnosis.
  • A thorough diagnostic approach combining clinical evaluation, imaging, and genetic testing is crucial.
  • Therapeutic management aligns with heart failure guidelines, with a lower threshold for anticoagulation.